These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31911079)

  • 1. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
    Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM
    Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
    Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
    Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
    Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
    Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
    J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
    Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
    Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
    Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
    Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A
    Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
    Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
    Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LOXL2 in cancer: regulation, downstream effectors and novel roles.
    Wen B; Xu LY; Li EM
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
    de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
    J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
    Hong X; Yu JJ
    Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
    Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
    Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
    Peng DH; Ungewiss C; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Uraoka N; Mino B; Behrens C; Wistuba II; Han RI; Wanna CA; Fahrenholtz M; Grande-Allen KJ; Creighton CJ; Gibbons DL
    Oncogene; 2017 Apr; 36(14):1925-1938. PubMed ID: 27694892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
    Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
    Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.
    Brekhman V; Lugassie J; Zaffryar-Eilot S; Sabo E; Kessler O; Smith V; Golding H; Neufeld G
    FASEB J; 2011 Jan; 25(1):55-65. PubMed ID: 20802105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization.
    Canesin G; Cuevas EP; Santos V; López-Menéndez C; Moreno-Bueno G; Huang Y; Csiszar K; Portillo F; Peinado H; Lyden D; Cano A
    Oncogene; 2015 Feb; 34(8):951-64. PubMed ID: 24632622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
    Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J
    Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
    Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
    J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.